Congestive heart failure classification: Difference between revisions

Jump to navigation Jump to search
Mdoherty (talk | contribs)
Mdoherty (talk | contribs)
No edit summary
Line 1: Line 1:
{{Infobox_Disease |
{{Template:Congestive heart failure}}
  Name          = Heart failure |
{{CMG}}
  Image          = |
  Caption        = |
  DiseasesDB    = 16209 |
  ICD10          = {{ICD10|I|50|0|i|50}} |
  ICD9          = {{ICD9|428.0}} |
  ICDO          = |
  OMIM          = |
  MedlinePlus    = 000158 |
  eMedicineSubj  = med |
  eMedicineTopic = 3552 |
  MeshID        = D006333|
}}


{{SI}}
'''Associate Editor-In-Chief:''' {{CZ}}; Saleh El Dassouki, M.D [mailto:seldassouki@hotmail.com], Atif Mohammad, MD
{{WikiDoc Cardiology Network Infobox}}
{{WikiDoc Cardiology News}}
{{CMG}}


{{EJ}}
{{EJ}}

Revision as of 12:49, 29 June 2011

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure classification

CDC on Congestive heart failure classification

Congestive heart failure classification in the news

Blogs on Congestive heart failure classification

Directions to Hospitals Treating Congestive heart failure classification

Risk calculators and risk factors for Congestive heart failure classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Saleh El Dassouki, M.D [3], Atif Mohammad, MD

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Classification Schemes of Congestive Heart Failure

Framingham Criteria

Major Criteria

Minor Criteria

Boston Criteria of Congestive Heart Failure

  • Category I: History
  • Category II: Physical Examination
  • Category III: Chest Radiography

No more than 4 points are allowed from each of three categories; hence the composite score (the sum of the subtotal from each category) has a possible maximum of 12 points.

The diagnosis of heart failure is classified as "definite" at a score of 8 to 12 points, "possible" at a score of 5 to 7 points, and "unlikely" at a score of 4 points or less.

New York Heart Association Criteria (NYHA)

  • NYHA I: No symptoms with ordinary activity.
  • NYHA II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.
  • NYHA III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
  • NYHA IV: Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency present at rest.

ACC/AHA Classification of Chronic Heart Failure

Classification System based on structural and symptomatic stages of the syndrome.

Introduced to emphasize the natural history of the heart failure syndrome and to identify ealier opportunities to intervene and prevent advancement. (Use along with NYHA starting when symptoms develop (Stages C-D). Stage A: patients at risk of developing heart failure but who have no structural heart disease at present. Stage B: patients with structural heart disease but no symptoms. Stage C: patients with structural heart disease and symptomatic heart failure. Stage D: patients with severe refractory heart failure.

Stage A

Patients “at Risk”

Stage B

Patients with structural heart disease, but no history of signs or symptoms of heart failure.

Stage C

Underlying structural heart disease and symptoms of heart failure.

  • Dyspnea or fatigue due to left ventricular systolic dysfunction.
  • Asymptomatic patients receiving treatment for prior symptoms of heart failure.

Stage D

Despite of maximal medical therapy, symptoms of heart failure at rest and advanced structural heart disease.

  • Being considered for advance options including LVAD and heart transplantation
  • Requiring continuous inotropic or mechanical support
  • Recieving or being considered for palliative care/end of life care.

References

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. JACC 2009;xx: xx-xxx. Template:SIB

Template:WH Template:WS